Interaction Between Rosuvastatin and Brilinta (Ticagrelor)
Rosuvastatin can be safely combined with ticagrelor without dose restrictions, though clinicians should monitor for muscle-related adverse effects as ticagrelor increases rosuvastatin exposure approximately 2-3 fold through BCRP inhibition. 1
Mechanism of Interaction
The interaction occurs primarily through breast cancer resistance protein (BCRP) inhibition in the intestine rather than through CYP450 metabolism 2, 3:
- Ticagrelor inhibits BCRP-mediated transport of rosuvastatin with an IC50 of 0.36 μM, leading to increased systemic absorption 3
- A clinical pharmacokinetic study demonstrated that ticagrelor 90 mg increased rosuvastatin AUC by 2.6-fold (90% CI: 1.8-3.8) and peak concentration by 2.6-fold (90% CI: 1.7-4.0) 2
- Ticagrelor also prolonged rosuvastatin half-life from 3.1 to 6.6 hours and decreased renal clearance by 11% 2
- The FDA drug label for rosuvastatin confirms ticagrelor increases rosuvastatin plasma concentrations and recommends monitoring for statin-related adverse effects 4
Official Guideline Recommendations
The American Heart Association (2016) explicitly states there are no reports of significant interactions when ticagrelor is used with rosuvastatin, and no dosing restrictions are needed. 1
This contrasts sharply with simvastatin and lovastatin, where:
- Simvastatin doses must not exceed 40 mg daily when combined with ticagrelor 1
- Lovastatin doses should similarly not exceed 40 mg daily 1
- These restrictions exist because ticagrelor increases simvastatin exposure through CYP3A4 inhibition by 81% (Cmax) and 56% (AUC) 1
Clinical Safety Considerations
Despite the lack of formal dosing restrictions, real-world evidence suggests caution is warranted 5, 6, 3:
- The WHO pharmacovigilance database identified increased rhabdomyolysis reporting when ticagrelor was combined with rosuvastatin (ROR 1.90,95% CI: 1.42-2.54) compared to rosuvastatin alone 5
- Over 40 cases of rhabdomyolysis have been reported with concomitant ticagrelor and rosuvastatin, including 3 fatal outcomes 3
- Case reports document rhabdomyolysis occurring 1-6 months after initiating combination therapy 3, 7
Practical Management Algorithm
For patients requiring both medications:
Combination therapy is reasonable per AHA guidelines, but requires vigilant monitoring 1
Monitor closely for muscle-related symptoms including:
Check baseline and follow-up creatine kinase (CK) levels, particularly in high-risk patients:
Consider dose reduction of rosuvastatin when initiating ticagrelor, given the 2.6-fold increase in exposure 2
The FDA label for Brilinta specifically warns that patients receiving rosuvastatin may experience increased plasma concentrations and should be monitored for statin-related adverse effects 8
Key Distinction from Other Statins
Rosuvastatin differs fundamentally from simvastatin/lovastatin in its interaction profile 1:
- Rosuvastatin is not metabolized by CYP3A4, eliminating the major pathway of interaction seen with simvastatin/lovastatin 4
- The interaction is primarily through intestinal BCRP inhibition rather than hepatic metabolism 2, 3
- Ticagrelor does not inhibit OATP1B-mediated hepatic uptake of rosuvastatin at clinically relevant concentrations 2
Common Pitfall to Avoid
Do not assume rosuvastatin is completely safe with ticagrelor simply because guidelines state "no dosing restrictions." The 2016 AHA guidelines predate the 2024 pharmacokinetic studies demonstrating significant exposure increases 2 and the WHO pharmacovigilance analysis showing increased rhabdomyolysis reporting 5. The combination requires active monitoring despite the absence of formal dose caps.